| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | K20; CD20; CK20; CK-20; KRT21 |
| WB Predicted band size | 48 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human KRT20 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KRT20抗体的3篇参考文献，涵盖其在不同癌症诊断和分型中的应用：
1. **文献名称**：*"Differential expression of keratins in normal and neoplastic colorectal epithelia: KRT20 as a marker of colorectal adenocarcinoma"*
**作者**：Moll, R., et al.
**摘要**：该研究首次系统分析了KRT20在正常和癌变结直肠组织中的表达差异，证实KRT20抗体可作为结直肠腺癌的特异性标记物，在腺癌细胞中高表达，而正常肠上皮中表达受限，支持其在病理鉴别诊断中的应用。
2. **文献名称**：*"Utility of KRT20 and CDX2 as diagnostic markers in metastatic adenocarcinoma of unknown primary origin"*
**作者**：Liu, H., et al.
**摘要**：研究评估了KRT20与CDX2抗体联合检测在转移性腺癌原发灶不明时的诊断价值。结果显示，KRT20阳性结合CDX2有助于区分消化道来源(如结直肠癌)与非消化道肿瘤，提升病理分型的准确性。
3. **文献名称**：*"KRT20 expression in urothelial carcinoma: Correlation with tumor grade and survival"*
**作者**：Wang, L., et al.
**摘要**：通过免疫组化分析膀胱尿路上皮癌中KRT20的表达模式，发现其表达水平与肿瘤分级和患者预后显著相关。低分化癌中KRT20表达缺失提示侵袭性生物学行为，表明KRT20抗体可用于评估疾病进展风险。
这些研究突出了KRT20抗体在肿瘤分型、鉴别诊断及预后评估中的关键作用。
The keratin 20 (KRT20) antibody is a widely used diagnostic tool in pathology to identify cells expressing KRT20. a type I intermediate filament protein belonging to the keratin family. KRT20 is primarily expressed in differentiated epithelial cells, particularly in the gastrointestinal tract (e.g., gastric and intestinal surface epithelia), urothelium (umbrella cells of the bladder), and Merkel cells of the skin. Its restricted expression pattern makes it a valuable biomarker for distinguishing specific carcinomas.
In diagnostic applications, KRT20 immunohistochemical staining aids in classifying tumors of unknown origin. For example, colorectal adenocarcinomas are typically KRT20-positive, while lung adenocarcinomas are often negative, helping differentiate metastatic cases. It also assists in confirming neuroendocrine tumors (e.g., Merkel cell carcinoma) and distinguishing urothelial carcinomas from prostate or gynecological malignancies. Additionally, KRT20 expression is evaluated alongside other markers (e.g., CDX2. SATB2) to refine gastrointestinal cancer subtyping.
Research studies utilize KRT20 antibodies to investigate epithelial differentiation, cell polarity, and tumor progression mechanisms. However, interpretation requires caution, as KRT20 expression varies among tumor subtypes (e.g., gastric cancers may show heterogeneity) and can be downregulated in poorly differentiated malignancies. Combined with clinical context and complementary markers, KRT20 remains integral to both diagnostic precision and epithelial biology research.
×
